Cutting-Edge Science and Innovation

REVOLUTIONIZING FERTILITY
& REPRODUCTIVE HEALTH

Making reproductive health solutions more accessible, effective, and affordable for individuals and families on their fertility journey.

First-in-Class Male Fertility Patent for Sale

Aqua Fem, LLC is offering the IP rights to AF — a proprietary compound that increases human sperm motility by over 700% on contact. Backed by strong preclinical data and protected by international patents, AF represents a scalable solution to a critical and underserved need in a $38B global fertility market.

Learn More

Download the AF Overview

MEET OUR TEAM

Leaders in Fertility and Groundbreaking Science

Aqua Fem’s founding team brings deep expertise in reproductive science, regulatory strategy, biotech commercialization, and consumer health. They are advancing solutions that expand access and improve outcomes in fertility care.

Learn More

INSIGHTS & THOUGHT LEADERSHIP

Male Reproductive Health, Infertility Innovation, Biotech Strategy

From investor readiness to male reproductive health, explore timely insights from Aqua Fem's leadership.

Read The Articles

Sperm Motility: The Most Overlooked Bottleneck in Male Fertility Innovation

Sperm motility is a critical but under-addressed driver of male infertility. Learn why improving sperm function—not just count—is central to next-generation fertility solutions and strategic acquisition-ready assets.

man in business suit pressing virtual screen with words Intellectual Property

De-Risking Biotech Deals: Why Ready-to-Transfer IP Accelerates Commercialization

Biotech leader Roderick Duell explains why validated, de-risked, ready-to-transfer IP is becoming the preferred target for investors and acquirers. Learn how scientific clarity, regulatory preparation, and due-diligence readiness increase valuation and accelerate market entry.

The Mitochondrial Engine: Powering Sperm Motility and Fertility

Fertility scientist Dr. Eric Lacy explains how mitochondrial function and ATP generation drive sperm motility — and why innovations like Aqua Fem’s AF compound may redefine male fertility treatments.

PATENT-PROTECTED IP ASSET READY FOR ACQUISITION

Male Infertility Therapy | New Molecular Entity

LETS TALK

Ready to Learn More?

We’re actively seeking a strategic acquirer to bring AF to market. Download the overview or reach out to schedule an introductory call.